Want to see SLN full AI Analyst Report?
SLN Stock Chart & Stats
$7.53
-$0.25(-3.72%)
At close: 4:00 PM EST
$7.53
-$0.25(-3.72%)
Day’s Range― - ―
52-Week Range$4.19 - $11.19
Previous CloseN/A
Volume50.54K
Average Volume (3M)524.07K
Market Cap
$495.96M
Enterprise Value$178.98
Total Cash (Recent Filing)$70.08M
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.32
Shares Outstanding47,234,610
10 Day Avg. Volume449,874
30 Day Avg. Volume524,065
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.33Price Target Upside462.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.53
Revenue Forecast (FY)$3.35M
Bulls Say, Bears Say
Bulls Say
Proprietary GalNAc SiRNA Delivery PlatformSilence’s optimized siRNA/GalNAc delivery toolbox is a durable competitive asset: delivery determines RNAi therapeutic success, and a validated liver-targeting platform supports multiple programs, increases partnering/licensing value, and raises technical barriers for competitors over years.
Encouraging Phase 1 SANRECO Divesiran DataRobust Phase 1 safety and durable efficacy signals materially de-risk the divesiran program long-term. Demonstrated reduction in phlebotomy and QoL gains support differentiated positioning in polycythemia vera, strengthen future partner interest and bolster the case for regulatory and commercial progression.
Low Financial Leverage / Minimal DebtNear-zero debt gives Silence durable financial flexibility to pursue R&D and partnerships without immediate leverage risk. Low fixed obligations reduce insolvency risk and improve options to raise capital or negotiate collaborations on favorable terms when development milestones are reached.
Bears Say
Sustained Negative Operating And Free Cash FlowPersistent cash burn is a structural constraint: sustained negative operating and free cash flow forces repeated capital raises or reliance on partners, increases dilution risk, and limits the company’s ability to advance multiple trials or scale commercial capabilities without external funding.
Large Operating And Net Losses Versus Small Revenue BaseThe company’s losses far exceed its modest revenue, indicating limited operating leverage and an R&D-heavy cost structure. This makes profitability distant, increases dependency on milestone/licensing income to fund development, and raises execution risk if clinical timelines slip.
Equity Erosion And Negative Returns On EquityOngoing losses have materially depleted shareholder equity and produced negative ROE, weakening the company’s capital base. This erodes non-dilutive financing capacity, may force more dilutive raises or strategic deals, and constrains long-term autonomy over program prioritization.
Silence Therapeutics News
SLN FAQ
What was Silence Therapeutics Plc’s price range in the past 12 months?
Silence Therapeutics Plc lowest stock price was $4.19 and its highest was $11.19 in the past 12 months.
What is Silence Therapeutics Plc’s market cap?
Silence Therapeutics Plc’s market cap is $495.96M.
When is Silence Therapeutics Plc’s upcoming earnings report date?
Silence Therapeutics Plc’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Silence Therapeutics Plc’s earnings last quarter?
Silence Therapeutics Plc released its earnings results on May 07, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.129 by $0.019.
Is Silence Therapeutics Plc overvalued?
According to Wall Street analysts Silence Therapeutics Plc’s price is currently Undervalued.
Does Silence Therapeutics Plc pay dividends?
Silence Therapeutics Plc does not currently pay dividends.
What is Silence Therapeutics Plc’s EPS estimate?
Silence Therapeutics Plc’s EPS estimate is -0.14.
How many shares outstanding does Silence Therapeutics Plc have?
Silence Therapeutics Plc has 47,234,610 shares outstanding.
What happened to Silence Therapeutics Plc’s price movement after its last earnings report?
Silence Therapeutics Plc reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.129. Following the earnings report the stock price went down -5.571%.
Which hedge fund is a major shareholder of Silence Therapeutics Plc?
Currently, no hedge funds are holding shares in SLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (462.20% Upside)
$42.33 (462.20% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 70.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.81%
12-Months-Change
Fundamentals
Return on Equity
-121.71%
Trailing 12-Months
Asset Growth
-37.87%
Trailing 12-Months
Company Description
Silence Therapeutics Plc
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
SLN Stock 12 Month Forecast
Average Price Target
$42.33
▲(462.20% Upside)
Technical Analysis
Ownership Overview
22.15%
Insiders
0.10% Mutual Funds
32.00% Other Institutional Investors
45.16% Public Companies and
Individual Investors